| |
NewswireTODAY - /newswire/ -
Allentown, PA, United States, 2026/01/02 - A breakthrough medical technology designed to restore controllable nipple projection for patients undergoing reconstructive procedures after mastectomy - OctoNervs.com.
|
| |
OctoNerv, LLC is proud to announce the successful development of the first fully functional electronic prototype of the Electronic Breast Nipple Implant (EBNI) a breakthrough medical technology designed to restore controllable nipple projection for patients undergoing reconstructive procedures after mastectomy.
The EBNI prototype integrates a soft silicone outer form with internal micro-actuators, pressure sensing, wireless charging, and Bluetooth Low Energy (BLE) communication. The system is controlled through a mobile application developed to support clinical testing, diagnostics, and future configuration tools for reconstructive surgeons.
The current prototype represents an early feasibility model and is not the final product. It is an investigational design intended to demonstrate core functionality, and the final clinical version will undergo further refinement through ongoing Research and Development. Future improvements to materials, components, and miniaturization will progress as additional funding becomes available.
This milestone demonstrates the feasibility of a dynamic, electronically enhanced implant that can deliver predictable and controllable projection addressing one of the most persistent challenges in post-mastectomy nipple reconstruction.
“This technology was built for survivors who have been told too many times that their options are limited,” said Steven G. Breeden, Founder & CEO of OctoNerv. “The successful prototype proves that we can bring movement, control, and new possibilities to an area of reconstruction that has been unchanged for decades.”
OctoNerv (octonervs.com) will now begin preparing for preclinical form-factor integration, expanded engineering testing, and early collaboration with surgical centers and research institutions. As development continues, the company remains committed to safety, transparency, and patient-centered design principles.
Additional updates will be released as OctoNerv progresses toward preclinical studies, regulatory pathway planning, and formal clinical partnerships.
|
steven[.]octonervs.com 
